RELMADA THERAPEUTICS RLMD 深 沪
已收盘 02-06 16:00:00 美东时间
3.88
+0.280
+7.78%
华盛通- 最 高3.95
- 今 开3.61
- 成交量 47.88万股
- 最 低 3.60
- 昨 收 3.60
- 总市值 2.85亿
- 52周最高 5.12
- 市盈率 静 --
- 换手率 0.65%
- 52周最低 0.2404
- 委 比 18.50%
- 总股本 7333.36万
- 历史最高 54.00
- 量 比 0.70
- 振 幅 9.72%
- 历史最低 0.2404
- 每 手 1
- 风险率 1.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
Leerink Partners Upgrades Relmada Therapeutics to Outperform, Announces $8 Price Target
Leerink Partners analyst Andrew Berens upgrades Relmada Therapeutics (NASDAQ:RLMD) from Market Perform to Outperform and announces $8 price target.
01-23 20:07
Relmada Therapeutics Receives Written Feedback from FDA Regarding NDV-01 In Second-Line Refractory, High-Grade BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ
In its written response to Relmada's Type B pre-IND submission, the FDA indicated that a single-arm, open-label clinical trial in this high-grade, BCG-unresponsive with CIS population is an appropriate registrational
01-12 20:16
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
Relmada Therapeutics To Present 6-Month Follow-Up Data From Ongoing Phase 2 Study Of NDV-01 In Development For Non-Muscle Invasive Bladder Cancer, At SUO 2025
Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safetyRelmada plans to advance NDV-01, a sustained release
2025-12-03 20:36
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
2025-11-20 10:28
Mizuho Upgrades Relmada Therapeutics to Outperform, Raises Price Target to $10
Mizuho analyst Uy Ear upgrades Relmada Therapeutics (NASDAQ:RLMD) from Neutral to Outperform and raises the price target from $1 to $10.
2025-11-19 22:36
Relmada Therapeutics Q3 EPS $(0.30) Misses $(0.04) Estimate
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.04) by 650 percent. This is a 58.33 percent increase over losses of $(0.72) per share
2025-11-14 05:03
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
Relmada Therapeutics appointed Dr. Max Kates to its Clinical Advisory Board to support the Phase 3 development of NDV-01 for non-muscle invasive bladder cancer (NMIBC). Dr. Kates, renowned for leading the Phase 3 BRIDGE trial, brings extensive experience in bladder cancer treatment. The Phase 3 program for NDV-01, a sustained-release formulation of gemcitabine and docetaxel, is expected to begin in H1 2026. The company aims to leverage Dr. Kates'...
2025-10-07 11:30
Relmada Therapeutics Updates Corporate Presentation on NDV-01
Relmada Therapeutics ( ($RLMD) ) has shared an announcement. On September 17, 2...
2025-09-17 19:59
